UKVIA Expresses Disappointment Over Welsh Tobacco Control Strategy

Aug.11.2022
UKVIA Expresses Disappointment Over Welsh Tobacco Control Strategy
The Welsh Tobacco Control Strategy lacks support for e-cigarettes and misses a significant opportunity for smoking cessation, says UKVIA.

The newly released Tobacco Control Strategy (TCS) in Wales has stated that it has not yet developed a position on e-cigarettes. The UKVIA has stated that, given the support of e-cigarettes in other parts of the UK, it will continue to engage with Welsh policymakers.


A plan to reduce smoking rates in Wales and achieve a "smoke-free" status by 2030 has been recently released. However, the plan has been criticized by the UK Vaping Industry Association (UKVIA) for lacking support for electronic cigarettes, which they describe as a missed opportunity. The UKVIA is the largest industry association representing the e-cigarette industry in the United Kingdom.


John Dunne, CEO of UKVIA stated, "While there are many commendable aspects to the strategy for reducing smoking rates in Wales, it is disappointing that the Welsh government hasn't gone further to seize this golden opportunity to embrace and advocate for e-cigarettes as the best and most effective way to help people quit smoking for good.


Although the Welsh TCS did mention e-cigarettes, it was only briefly noted that the Welsh government needs to develop its stance on e-cigarettes.


Dunne went on to say, "For this reason, we will continue to collaborate with the Welsh government, as in the recent example of the Khan review on smoking, which concluded that promoting e-cigarettes is absolutely crucial for achieving a smoke-free UK by 2030.


Welsh TCS has brought up the issue of preventing children and young people from smoking and using e-cigarettes - a topic that UKVIA has strongly advocated for. Dunne stated: "We welcome the Welsh government's plan to prevent young people from accessing e-cigarettes.


As an association, we have called on the UK government to impose stricter regulations on e-cigarette retailers who sell to young people. We recommend a fine of £10,000 for those caught in violation.


Returning to Wales, TCS lacks support for e-cigarettes as a tool to quit smoking. Dunne added, "There is indisputable evidence that e-cigarettes are effective in helping adults quit smoking. Support is growing among the scientific, academic, healthcare, and political communities, all of which now recognize e-cigarettes as an important component in helping smokers quit.


While it is disappointing to see that the Welsh government has not taken a more proactive stance on e-cigarettes, it is important to engage with politicians and decision-makers in the region to showcase the value of these devices and help the country achieve its smoke-free goals. Failing to do so could have serious consequences for Wales' ability to reduce smoking rates and minimize harm.


Meanwhile, in Scotland, a survey of 2,170 individuals found that 41% of respondents reported that e-cigarettes helped them quit smoking. The survey also found that only one-sixth of respondents wished for stricter regulations on e-cigarettes, while half hoped for more relaxed regulations. Scotland's government is currently considering whether to ban in-store promotions of e-cigarettes.


Statement:


This article is compiled from third-party information and is intended for industry professionals for educational and informational purposes only.


This article does not necessarily represent the views of 2FIRSTS, and 2FIRSTS cannot verify the truth or accuracy of the article's content. The translation of this article is intended only for internal industry discussion and research purposes.


Due to limitations in translation skills, the translated article may not accurately convey the original meaning. Please refer to the original article for accuracy.


2FIRSTS maintains complete alignment with the Chinese government in regard to any domestic, Hong Kong, Macao, Taiwan, or foreign statements and positions.


All compiled information is owned by the original media and author. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Special Report | From Oversupply to Supply Gaps: Global Tobacco Leaf Markets Diverge Ahead of 2027
Special Report | From Oversupply to Supply Gaps: Global Tobacco Leaf Markets Diverge Ahead of 2027
Global tobacco leaf markets diverged sharply in 2026, with India cutting authorised FCV production amid oversupply while Malawi faced a supply shortfall. U.S. demand improved in some leaf categories, but growers in Brazil, Colombia, Tanzania and Zimbabwe faced pressure from prices, buyer access, costs and weather. With nicotine consumption patterns also shifting, 2027 will test whether supply, demand and grower profitability can move back toward balance.
Oct.26
Product | KT&G Launches lil HYBRID 3.0 Misty Rosé Edition II in South Korea With Two Pink Finishes at 88,000 Won
Product | KT&G Launches lil HYBRID 3.0 Misty Rosé Edition II in South Korea With Two Pink Finishes at 88,000 Won
South Korean tobacco company KT&G launched the limited-edition lil HYBRID 3.0 Misty Rosé Edition II on September 30, 2026, following the original Misty Rosé Edition introduced in November 2025. The new release comes in two pink finishes, Bloom Rosé and Viva Rosé, each priced at 88,000 won. Both versions initially went on sale through the lil Store online shop and lil MINIMALIUM flagship stores. From October 7, Bloom Rosé became available at approximately 1,500 lil Station retail outlets nationwide. The release retains the existing lil HYBRID 3.0 hybrid heated tobacco platform, with changes focused on exterior design and distribution.
product
Oct.10
2Firsts First Look|China to End VAT Export Rebates on Vape Devices and Nicotine in April 2027, Following Earlier Removal for HTP Devices and Nicotine Vapes
2Firsts First Look|China to End VAT Export Rebates on Vape Devices and Nicotine in April 2027, Following Earlier Removal for HTP Devices and Nicotine Vapes
China's Ministry of Finance and State Taxation Administration announced on October 12, 2026, that value-added tax (VAT) export rebates for vape devices, nicotine and its salts, and certain non-combustible inhalation products will be eliminated from April 1, 2027. The measure adds four tobacco- and nicotine-related customs codes, including 8543400010, which covers vape devices and qualifying empty pods. China previously eliminated rebates for nicotine-containing vaping products and devices under code 8543400090 in April 2026. According to industry classification information held by 2Firsts, the latter currently corresponds to heated tobacco devices. Export excise tax refund and exemption arrangements will remain unchanged.
Special Report
Oct.12
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Germany's Four-Year Tobacco Tax Plan Heads to Parliament as BAT, JTI and PMI Push for Changes
Germany's Four-Year Tobacco Tax Plan Heads to Parliament as BAT, JTI and PMI Push for Changes
Germany's parliament is scheduled to hold a first reading of amendments to the Tobacco Tax Act on September 24. The government plans annual tax increases from 2027 through 2030 covering cigarettes, heated tobacco, vaping liquids and other categories. It expects the reform to generate €756 million in additional revenue in 2027, rising to €3.589 billion in additional annual revenue by 2030. Ahead of the parliamentary debate, the German Association of the Tobacco Industry and Novel Products, or BVTE, launched the "Tabaksteuer mit Augenmaß" campaign backed by BAT, JTI, Philip Morris, Reemtsma and wholesale and retail groups.
Sep.23
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
French vaping company Kumulus Vape reported first-half 2026 revenue of €25.5 million, down 8.3% year over year, as its core B2B distribution business fell 11% to €21.6 million. B2C and store-network revenue rose 5.6% and 17.8%, respectively. Commercial margin increased to 26.3% from 21.7%, while net profit rose 24.1% to €0.8 million. The company attributed the profitability improvement to catalog optimization, logistics restructuring and the ramp-up of Labster, its in-house production unit for proprietary brands.
Market
Sep.17 by 2Firsts Perspectives